Characterization of Antibodies Directed against the Immunoglobulin Light κ Chain Variable Chain Region (VK) of Hepatitis C Virus-Related Type-II Mixed Cryoglobulinemia and B-Cell Proliferations

被引:11
作者
de Re, Valli [1 ]
Simula, Maria Paola
Pavan, Alessandro
Garziera, Marica
Marin, Dolores
Dolcetti, Riccardo [2 ]
de Vita, Salvatore [3 ]
Sansonno, Domenico [4 ]
Geremia, Silvano [5 ]
Toffoli, Giuseppe
机构
[1] Ctr Riferimento Oncol, Expt & Clin Pharmacol Unit, DOMERT,Natl Canc Inst, Mol Oncol Translat Res Dept,IRCCS, I-33081 Aviano, PN, Italy
[2] Ctr Riferimento Oncol, Natl Canc Inst, Canc Bioimmunotherapy Unit, Ist Ricovero & Cura Carattere Sci, I-33081 Aviano, PN, Italy
[3] Univ Udine, Azienda Osped, Clin Rheumatol, I-33100 Udine, Italy
[4] Univ Bari, Dept Internal Med & Clin Oncol, I-70121 Bari, Italy
[5] Univ Trieste, Dept Chem Sci, I-34127 Trieste, Italy
来源
CONTEMPORARY CHALLENGES IN AUTOIMMUNITY | 2009年 / 1173卷
关键词
HCV; idiotype; single-chain immunoglobulin variable fragment; monoclonal antibody; type II mixed cryoglobulinemia; NHL; lymphoma; SJOGRENS-SYNDROME; ANTIGEN RECEPTOR; LYMPHOMAS; AUTOIMMUNITY; SEGMENTS; IGM;
D O I
10.1111/j.1749-6632.2009.04677.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Autoimmune type-II cryoglobulinemia (H-MC) is sustained by hepatitis C virus (HCV) infection and B-cell (oligo)clones. This is the reason why the disease may be considered an "indolent B-cell lymphoma (NHL)." B clones show a restricted use of immunoglobulin variable genes (BCR), in particular in the use of the variable kappa (VK)3-20/15 light chain, and show a homology between their BCR functional regions and those of autoimmune rheumatoid factors. We underlined the BCR unique repertoire with frequent rheumatoid factor activity also observed in other autoimmune disorders associated with NHL. The immunoglobulin idiotype is a clonal B-cell marker and an ideal target for immunotherapy. Five monoclonal antibodies were produced in our laboratory toward the VK3-20 of a subject with HCV infection and a II-MC-associated NHL. Epitope determination was performed using the epitope excision approach. Monoclonal antibody reactivity was tested in vitro in ELISA, Western blot, and cytofluorimetry. Data confirmed that a panel of antibodies, reactive against shared idiotypes, can be produced from patients with HCV-associated B-cell lymphoproliferative diseases, thus obviating the need to produce an anti-idiotype antibody for each patient.
引用
收藏
页码:152 / 160
页数:9
相关论文
共 23 条
  • [1] Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity
    Bende, RJ
    Aarts, WM
    Riedl, RG
    de Jong, D
    Pals, ST
    van Noesel, CJM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (08) : 1229 - 1241
  • [2] BOMBEN R, 2008, BR J HAEMATOL
  • [3] Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia
    Charles, Edgar D.
    Green, Rashidah M.
    Marukian, Svetlana
    Talal, Andrew H.
    Lake-Bakaar, Gerond V.
    Jacobson, Ira M.
    Rice, Charles M.
    Dustin, Lynn B.
    [J]. BLOOD, 2008, 111 (03) : 1344 - 1356
  • [4] Anti-idiotype antibodies in cancer treatment
    de Cerio, A. Lopez-Diaz
    Zabalegui, N.
    Rodriguez-Calvillo, M.
    Inoges, S.
    Bendandi, M.
    [J]. ONCOGENE, 2007, 26 (25) : 3594 - 3602
  • [5] B-Cell lymphomas associated with HCV infection
    De Re, V.
    Caggiari, L.
    Simula, M. P.
    De Vita, S.
    Sansonno, D.
    Dolcetti, R.
    [J]. GASTROENTEROLOGY, 2007, 132 (03) : 1205 - 1207
  • [6] HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations
    De Re, V.
    Sansonno, D.
    Simula, M. P.
    Caggiari, L.
    Gasparotto, D.
    Fabris, M.
    Tucci, F. A.
    Racanelli, V.
    Talamini, R.
    Campagnolo, M.
    Geremia, S.
    Dammacco, F.
    De Vita, S.
    [J]. LEUKEMIA, 2006, 20 (06) : 1145 - 1154
  • [7] De Re V, 2000, INT J CANCER, V87, P211, DOI 10.1002/1097-0215(20000715)87:2<211::AID-IJC9>3.0.CO
  • [8] 2-8
  • [9] De Re V, 2002, EUR J IMMUNOL, V32, P903, DOI 10.1002/1521-4141(200203)32:3<903::AID-IMMU903>3.0.CO
  • [10] 2-D